Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
Merus N.V. (Nasdaq: MRUS) will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 12:45 p.m. ET. Bill Lundberg, M.D., the President and CEO, will represent the clinical-stage oncology company known for developing innovative multispecific antibodies, including Biclonics® and Triclonics®. A webcast of the event can be accessed on the Company's Investors page, and an archived version will be available post-event.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET.
The webcast of the fireside chat will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
FAQ
When is Merus N.V. participating in the Jefferies Healthcare Conference?
Who will represent Merus N.V. at the Jefferies Healthcare Conference?
Where can I watch the Merus N.V. fireside chat from the Jefferies Healthcare Conference?
What is the stock symbol for Merus N.V.?
What type of therapies does Merus N.V. focus on?
